scholarly journals Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway

Bioengineered ◽  
2022 ◽  
Vol 13 (1) ◽  
pp. 1931-1941
Author(s):  
Peng Wang ◽  
Yuanjing Hu ◽  
Pengpeng Qu ◽  
Ying Zhao ◽  
Jing Liu ◽  
...  
2021 ◽  
Author(s):  
Shahan Mamoor

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding protein tyrosine phosphatase, non-receptor type 6, PTPN6, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. PTPN6 expression was significantly higher in high-grade serous ovarian tumors relative to normal fallopian tube. PTPN6 expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of PTPN6 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. PTPN6 may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.


2021 ◽  
pp. jclinpath-2020-206927
Author(s):  
Maryam Ahmed Al Barashdi ◽  
Ahlam Ali ◽  
Mary Frances McMullin ◽  
Ken Mills

The leucocyte common antigen, protein tyrosine phosphatase receptor type C (PTPRC), also known as CD45, is a transmembrane glycoprotein, expressed on almost all haematopoietic cells except for mature erythrocytes, and is an essential regulator of T and B cell antigen receptor-mediated activation. Disruption of the equilibrium between protein tyrosine kinase and phosphatase activity (from CD45 and others) can result in immunodeficiency, autoimmunity, or malignancy. CD45 is normally present on the cell surface, therefore it works upstream of a large signalling network which differs between cell types, and thus the effects of CD45 on these cells are also different. However, it is becoming clear that CD45 plays an essential role in the innate immune system and this is likely to be a key area for future research. In this review of PTPRC (CD45), its structure and biological activities as well as abnormal expression of CD45 in leukaemia and lymphoma will be discussed.


2021 ◽  
Vol 26 ◽  
pp. 100974
Author(s):  
Shaoting Zhang ◽  
Liangying Zhang ◽  
Zongying Jiang ◽  
Yue Guo ◽  
Hui Zhao ◽  
...  

2020 ◽  
Vol 11 ◽  
Author(s):  
Larissa Hering ◽  
Egle Katkeviciute ◽  
Marlene Schwarzfischer ◽  
Philipp Busenhart ◽  
Claudia Gottier ◽  
...  

2008 ◽  
Vol 40 (8) ◽  
pp. 946-948 ◽  
Author(s):  
Barbara Schormair ◽  
David Kemlink ◽  
Darina Roeske ◽  
Gertrud Eckstein ◽  
Lan Xiong ◽  
...  

PLoS ONE ◽  
2010 ◽  
Vol 5 (3) ◽  
pp. e9641 ◽  
Author(s):  
Victoria Wang ◽  
David A. Davis ◽  
Ravindra P. Veeranna ◽  
Muzammel Haque ◽  
Robert Yarchoan

PLoS ONE ◽  
2013 ◽  
Vol 8 (8) ◽  
pp. e72384 ◽  
Author(s):  
Marianne R. Spalinger ◽  
Silvia Lang ◽  
Stephan R. Vavricka ◽  
Michael Fried ◽  
Gerhard Rogler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document